Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol. Co. has marketed Korlym (mifepristone) in the U.S. for the treatment of patients with Cushing's syndrome. Co.'s primary compounds have entered the clinic as potential treatments for serious disorders, including Cushing's syndrome, solid tumors (such as ovarian cancer, castration-resistant prostate cancer and adrenocortical cancer with cortisol excess), antipsychotic induced weight gain and non-alcoholic steatohepatitis. The CORT stock yearly return is shown above.
The yearly return on the CORT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CORT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|